| Old Articles: <Older 6551-6560 Newer> |
|---|
 |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow.   |
The Motley Fool
August 10, 2010
Brian Orelli |
Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option. |
The Motley Fool
August 10, 2010
David Meier |
Is Bruker Corp. Growing Foolishly? Bruker Corp.'s track record of creating value as it grows makes the life sciences and materials research company well worth considering. |
The Motley Fool
August 10, 2010
Seth Jayson |
Marginal Performance at Abbott Laboratories Keep your eye on margins. |
The Motley Fool
August 10, 2010
Seth Jayson |
Marginal Performance at Alcon The more Alcon keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
August 10, 2010
Todd Wenning |
Dividend Report Card: AstraZeneca Does this drugmaker's dividend pass the test? |
The Motley Fool
August 10, 2010
David Meier |
Is Amedisys Growing Foolishly? There's a right way and a wrong way for home health-care provider Amedisys to grow. |
The Motley Fool
August 10, 2010
Charly Travers |
PDL BioPharma's Magic Formula If you want low-fuss investing options that aren't mutual funds or exchange-traded funds, you should consider a mechanical investing strategy. See how it works with this BioPharma stock. |
The Motley Fool
August 10, 2010
David Meier |
Would Jeremy Grantham Buy Alcon? The seasoned pro thinks high-quality companies are on sale. Let's find the bargains. |
| <Older 6551-6560 Newer> Return to current articles. |
